Analyzing the Price-to-Earnings Ratio of Apyx Medical Corp (APYX)

The 36-month beta value for APYX is also noteworthy at 1.12. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”

The public float for APYX is 30.16M, and at present, short sellers hold a 5.19% of that float. The average trading volume of APYX on April 03, 2024 was 162.47K shares.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

APYX) stock’s latest price update

Apyx Medical Corp (NASDAQ: APYX)’s stock price has soared by 8.03 in relation to previous closing price of 1.37. Nevertheless, the company has seen a gain of 16.54% in its stock price over the last five trading days. Seeking Alpha reported 2024-03-21 that Apyx Medical Corporation (APYX) Q4 2023 Earnings Call Transcript

APYX’s Market Performance

APYX’s stock has risen by 16.54% in the past week, with a monthly drop of -28.85% and a quarterly drop of -43.51%. The volatility ratio for the week is 8.44% while the volatility levels for the last 30 days are 10.50% for Apyx Medical Corp The simple moving average for the past 20 days is -11.36% for APYX’s stock, with a -55.24% simple moving average for the past 200 days.

Analysts’ Opinion of APYX

Many brokerage firms have already submitted their reports for APYX stocks, with Stephens repeating the rating for APYX by listing it as a “Overweight.” The predicted price for APYX in the upcoming period, according to Stephens is $8 based on the research report published on July 14, 2023 of the previous year 2023.

Lake Street, on the other hand, stated in their research note that they expect to see APYX reach a price target of $12. The rating they have provided for APYX stocks is “Buy” according to the report published on May 20th, 2022.

Dougherty & Company gave a rating of “Buy” to APYX, setting the target price at $9 in the report published on April 02nd of the previous year.

APYX Trading at -27.99% from the 50-Day Moving Average

After a stumble in the market that brought APYX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -81.43% of loss for the given period.

Volatility was left at 10.50%, however, over the last 30 days, the volatility rate increased by 8.44%, as shares sank -30.52% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -25.63% lower at present.

During the last 5 trading sessions, APYX rose by +16.54%, which changed the moving average for the period of 200-days by -78.55% in comparison to the 20-day moving average, which settled at $1.6372. In addition, Apyx Medical Corp saw -43.51% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at APYX starting from HILL MATTHEW C, who purchase 2,500 shares at the price of $2.19 back on Dec 12 ’23. After this action, HILL MATTHEW C now owns 2,500 shares of Apyx Medical Corp, valued at $5,475 using the latest closing price.

Goodwin Charles D. II, the Chief Executive Officer of Apyx Medical Corp, purchase 50,000 shares at $1.57 during a trade that took place back on Nov 14 ’23, which means that Goodwin Charles D. II is holding 90,000 shares at $78,500 based on the most recent closing price.

Stock Fundamentals for APYX

Current profitability levels for the company are sitting at:

  • -0.31 for the present operating margin
  • 0.51 for the gross margin

The net margin for Apyx Medical Corp stands at -0.33. The total capital return value is set at -0.26. Equity return is now at value -58.22, with -28.57 for asset returns.

Based on Apyx Medical Corp (APYX), the company’s capital structure generated 0.56 points at debt to capital in total, while cash flow to debt ratio is standing at -0.1. The debt to equity ratio resting at 1.26. The interest coverage ratio of the stock is -13.19.

Currently, EBITDA for the company is -19.26 million with net debt to EBITDA at 0.27. When we switch over and look at the enterprise to sales, we see a ratio of 0.82. The receivables turnover for the company is 4.01for trailing twelve months and the total asset turnover is 0.71. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.52.


In summary, Apyx Medical Corp (APYX) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts